Top View
- Oran B, Ciurea S, Marin D, Et Al. Safety Analysis of Intra-Patient Dose
- Flt3 Inhibitors in the Treatment of Flt3/Itd Aml: Overcoming Resistance and Defining a Therapeutic Index
- Crenolanib Is a Type I Tyrosine Kinase Inhibitor That Inhibits Mutant KIT D816 Isoforms Prevalent in Systemic Mastocytosis and Core Binding Factor Leukemia
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
- Preclinical Research
- Gists) with the D842V Mutation in the PDGFRA Gene NIHRIO (HSRIC) ID: 6438 NICE ID: 9677
- Hepatic Stellate Cells: Current State and Open Questions
- Improved Recovery from Liver Fibrosis by Crenolanib
- Breaching the Curation Bottleneck with Human-Machine Reading Symbiosis
- 2020 Medicines in Development ꟷ Cancer
- COMP Agenda of the 13-15 February 2018 Meeting
- Laminin B1-Keratin 19 Cascade Drives Tumor Progression at the Invasive Front of Human Hepatocellular Carcinoma
- Selleck-Inhibitor-Catalog-Low-Resolution-EN.Pdf
- Somatic Mutations in Salivary Duct Carcinoma and Potential Therapeutic Targets
- Collins, R., Et Al., Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can Be Safely
- Targeting Receptor Kinases in Colorectal Cancer
- Optimizing the Management of Acute Myeloid Leukemia: Individualized Therapy
- Download Product Insert (PDF)
- Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
- Crenolanib, a PDGFR Inhibitor, Suppresses Lung Cancer Cell Proliferation and Inhibits Tumor Growth in Vivo
- Rac1-Mediated Membrane Raft Localization of PI3K/P110b Is
- Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
- Oncology Drugs in the Pipeline
- Pdgfrα Up-Regulation Mediated by Sonic Hedgehog Pathway Activation Leads to BRAF Inhibitor Resistance in Melanoma Cells with BRAF Mutation
- Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
- Molecular Intelligence Summary MI-2013-12-26.0
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Resistance to Molecularly Targeted Therapies in Melanoma
- Correlation of PET/CT and CT RECIST Response in GIST Patients with PDGFRA D842V Gene Mutations Treated with Crenolanib
- Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
- Clinical Considerations for the Use of FLT3 Inhibitors in Acute Myeloid Leukemia T ⁎ Taylor M
- A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance To
- Overcoming Acquired BRAF Inhibitor Resistance in Melanoma Via Targeted Inhibition of Hsp90 with Ganetespib
- CTOS 2011 Poster
- Orphan Drug Designations and Approvals List As of 12‐01‐2014
- Downregulating Oncogenic Receptor
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- 1 2 3 4 Overcoming Myelosuppression Due to Synthetic Lethal Toxicity In
- Acute Myeloid Leukemia Positive − Crenolanib Is Active Against Models of Drug-Resistant FLT3-ITD
- Pdgfrα Up-Regulation Mediated by Sonic Hedgehog Pathway Activation Leads to BRAF Inhibitor Resistance in Melanoma Cells with BRAF Mutation
- Acute Myeloid Leukemia: Incorporating the Latest Advances Into Nursing Practice
- Enzyme Inhibitors Enzymes Are Biological Catalysts That Drive Various Reactions Within a Cell
- CNS Penetration of Tyrosine Kinase Inhibitors in Mouse Models Mohamed Elmeliegy University of Tennessee Health Science Center
- A View Into Upcoming Specialty and Traditional Drugs JANUARY 2019
- Inhibition of FLT3 in AML: a Focus on Sorafenib
- Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against AML Cells
- Vanflyta; INN-Quizartinib
- Enduring Materials Application – Medical Grand Rounds #1886
- Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments
- Molecular Characterisation of Cutaneous Melanoma: Creating a Framework for Targeted and Immune Therapies
- •• • 1::1 <::! Q. Search
- Gastrointestinal Stromal Tumor GEIS Symposium 2018
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms
- Tyrosine Kinase Receptors in Oncology
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML